Investigational drug · Phase 3
KN057
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor, Hemophilia a and B.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "KN057"
First trial start
2024
Jan 9, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KN057", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hemophilia A Without Inhibitor
- Hemophilia B Without Inhibitor
- Hemophilia a and B
- Hemophilia A With Inhibitor
- Hemophilia B With Inhibitor
- Hemophilia A or B
Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "KN057" as an intervention, largest first.
- Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsPivotal-lookingActive, not recruiting
Suzhou Alphamab Co., Ltd.Industry
NCT06569108 · 125 participants · Start Apr 1, 2024 · Primary completion Oct 15, 2026
Drug: KN057 · For: Hemophilia A Without Inhibitor; Hemophilia B Without Inhibitor
Sites: Tianjin, China
- Safety of KN057 Prophylaxis in Patients With Haemophilia A or BPivotal-lookingRecruiting
Suzhou Alphamab Co., Ltd.Industry
NCT07545395 · 70 participants (planned) · Start Mar 13, 2026 · Primary completion Dec 30, 2027
Drug: KN057 · For: Hemophilia A or B
Sites: Tianjin, China
- Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With InhibitorsPivotal-lookingActive, not recruiting
Suzhou Alphamab Co., Ltd.Industry
NCT06312475 · 53 participants · Start Jan 9, 2024 · Primary completion Oct 15, 2025
Drug: KN057 · For: Hemophilia A With Inhibitor; Hemophilia B With Inhibitor
Sites: Tianjin, China
- KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without InhibitorsNot yet recruiting
Suzhou Alphamab Co., Ltd.Industry
NCT06747416 · 24 participants (planned) · Start Sep 2, 2025 · Primary completion Sep 2, 2026
Drug: KN057 · For: Hemophilia a and B
Suzhou Alphamab Co., Ltd.Industry
NCT05421429 · 24 participants · Start Jul 7, 2022 · Primary completion Jan 17, 2024
Drug: KN057 doseⅠ; KN057 dose Ⅱ and 1 more · For: Hemophilia
Sites: Tianjin, China · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3.
Ju M, Xue F, Sun W, et al. · Haemophilia 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.